A phase II, randomized trial to evaluate the efficacy and safety of pemetrexed versus docetaxel as salvage chemotherapy in patients with non small cell lung cancer who have previously failed EGFR-TKI therapy.
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Docetaxel (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Dec 2015 New trial record